Sichuan Kelun Pharmaceutical (SHE:002422) subsidiary Sichuan Kelun Botai Biopharmaceutical obtained marketing approval from China's medical products administrator for its tagorizumab drug.
The drug is a monoclonal antibody targeting programmed cell death ligand 1, according to a Tuesday filing with the Shenzhen bourse. It is used for treating recurrent or metastatic nasopharyngeal carcinoma.
Shares of the company were down 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments